Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma.


Journal

European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985

Informations de publication

Date de publication:
Aug 2021
Historique:
revised: 28 04 2021
received: 05 02 2021
accepted: 29 04 2021
pubmed: 3 5 2021
medline: 25 12 2021
entrez: 2 5 2021
Statut: ppublish

Résumé

Bortezomib-related peripheral neuropathy (PN) affects a relevant proportion of multiple myeloma (MM) patients treated with melphalan, prednisone, and bortezomib (VMP). Empirical dose modifications have attempted to reduce toxicity without compromising efficacy. We retrospectively evaluated the dose-response and dose-toxicity relationships in 114 unselected untreated MM patients intended for treatment with VMP with subcutaneous bortezomib. Sixty-two patients (54%) completed the 9 scheduled cycles. Median treatment duration was 48 weeks (range 1-57), cumulative bortezomib dose was 41.8 mg/m Biweekly full-dose treatment in the first cycles has a major impact in depth of response. Depth of response, cumulative bortezomib dose, and treatment duration had an impact in prolongation of PFS.

Sections du résumé

BACKGROUND BACKGROUND
Bortezomib-related peripheral neuropathy (PN) affects a relevant proportion of multiple myeloma (MM) patients treated with melphalan, prednisone, and bortezomib (VMP). Empirical dose modifications have attempted to reduce toxicity without compromising efficacy.
PATIENTS AND METHODS METHODS
We retrospectively evaluated the dose-response and dose-toxicity relationships in 114 unselected untreated MM patients intended for treatment with VMP with subcutaneous bortezomib.
RESULTS RESULTS
Sixty-two patients (54%) completed the 9 scheduled cycles. Median treatment duration was 48 weeks (range 1-57), cumulative bortezomib dose was 41.8 mg/m
CONCLUSIONS CONCLUSIONS
Biweekly full-dose treatment in the first cycles has a major impact in depth of response. Depth of response, cumulative bortezomib dose, and treatment duration had an impact in prolongation of PFS.

Identifiants

pubmed: 33934417
doi: 10.1111/ejh.13643
doi:

Substances chimiques

Antineoplastic Agents 0
Bortezomib 69G8BD63PP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

246-254

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan-prednisone versus melphalan-prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase 3 VISTA trial. J Clin Oncol. 2010;28:2259-2266.
Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2010;86:23-31.
Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan and prednisone versus bortezomib, thalidomide and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomized trial. Lancet Oncol. 2010;11:934-941.
Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol. 2010;28:5101-5109.
Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomized, phase 3, noninferiority study. Lancet Oncol. 2011;12:431-440.
Mateos MV, Dimopuolos M, Cavo M, et al. Daratumumab plus bortezomib, melphalan, prednisone for untreated myeloma (ALCYONE). N Engl J Med. 2018;378(6):518-528.
Durie BG, Hoering A, Abidi M, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent immediate autologous stem-cell transplant (SWOG S0777): a randomized, open-label, phase 3 trial. Lancet. 2017;389:519-527.
Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:467-473.
Robak P, Robak T. Bortezomib for the treatment of hematologic malignancies: 15 years later. Drugs RD. 2019;19:73-92.
Mateos MV, Oriol A, Martinez-Lopez J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012;120:2581-2588.
Facon T, Lee J, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma (CLARION). Blood. 2019;133:1953-1963.
Merz M, Salwender H, Haenel M, et al. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica. 2016;101:e485-e487.
Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519-4529.
De Arriba F, Durán MS, Álvarez MÁ, et al. Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation. Semin Hematol. 2018;55:189-196.
Mateos MV, Richardson P, Dimopoulos M, et al. Effect of cumulative botezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015;90(4):314-319.
Van RF, Szymonifka J, Anaissie E, et al. Total therapy 3 for multiple myeloma: Prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood. 2010;116:1220-1227.
Mateos MV, Bringhen S, Richardson PG, et al. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomibmelphalan-prednisone regimens in previously untreated myeloma patients ineligible for highdose therapy. Haematologica. 2014;99:1114-1122.
Benboubker L, Dimopoulos M, Dispenzieri A, et al. Lenalidomide and Dexamethasone in transplant-ineligible patients with myeloma. N Engl Med. 2014;371:906-917.
Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784-792.
Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4:3295-3301.
Dimopoulos M, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet. 2017;18:1327-1337.

Auteurs

Gladys Ibarra (G)

Hematology Department, Catalan Institute of Oncology, Germans Trias i Pujol Hospital and Josep Carreras Research Institute, Badalona, Spain.

Marta Peña (M)

Hematology Department, Catalan Institute of Oncology, Duran i Reynals Hospital, L'Hospitalet, Spain.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.

Laura Abril (L)

Hematology Department, Catalan Institute of Oncology, Germans Trias i Pujol Hospital, Badalona, Spain.

Alicia Senín (A)

Hematology Department, Catalan Institute of Oncology, Germans Trias i Pujol Hospital, Badalona, Spain.

Clara Maluquer (C)

Hematology Department, Catalan Institute of Oncology, Duran i Reynals Hospital, L'Hospitalet, Spain.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.

Victoria Clapés (V)

Hematology Department, Catalan Institute of Oncology, Duran i Reynals Hospital, L'Hospitalet, Spain.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.

Cristina Baca (C)

Hematology Department, Catalan Institute of Oncology, Duran i Reynals Hospital, L'Hospitalet, Spain.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.

Gabriela Bustamante (G)

Hematology Department, Catalan Institute of Oncology, Duran i Reynals Hospital, L'Hospitalet, Spain.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.

Anna Sureda (A)

Hematology Department, Catalan Institute of Oncology, Duran i Reynals Hospital, L'Hospitalet, Spain.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.

Albert Oriol (A)

Hematology Department, Catalan Institute of Oncology, Germans Trias i Pujol Hospital and Josep Carreras Research Institute, Badalona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH